knowledge -WSS

knowledge

author：explore 2025-09-02 13:47:26 - browse：17

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： How dance can help nurses traumatized by Covid

WSS

How dance can help nurses traumatized by Covid

Dana Farber says 6 studies to be retracted and 31 corrected

At Orexo, a ‘turning point’ for everything but digital health

Google and Epic fight stronger regulation of AI in health care

To bolster infectious disease surveillance, genomics powerhouses team up

Medicare to cover more brain scans for Alzheimer’s patients

hotspot

knowledge

explore

Activists slam private health insurers over coverage restrictions

A pediatrician calls for Congress to pass the child tax credit deal

The high cost of giving birth even with insurance

Startup Neumora takes a novel depression drug to Phase 3

At least 13 dead in Texas as scorching temps continue

Dog Aging Project founders on what lies ahead after losing funding

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

At Orexo, a ‘turning point’ for everything but digital health

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Group opposing PBM reform sets lobbying record

hotspot

Maisha Meds is a PBM, but don't call it that

Future doctors need a strong humanities education

Cosmetics set for new safety regulation. Why the industry is on board

There's an unseen cost to disruptive road

Why hospitals are withdrawing from US News rankings

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

focus

focus

focus

explore